Alaunos Therapeutics (TCRT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alaunos Therapeutics, Inc. has successfully regained compliance with Nasdaq’s minimum $1.00 bid price requirement, ensuring its continued listing on The Nasdaq Capital Market. The company has met all necessary criteria and the issue regarding its listing has been resolved. It will, however, be under a mandatory panel monitor for the next year until February 16, 2025, to ensure ongoing compliance.
For further insights into TCRT stock, check out TipRanks’ Stock Analysis page.